F.D.A. Vaccine Official Resigns Amid Controversy
The recent resignation of Dr. Vinay Prasad, a significant figure in the FDA’s vaccine division, has sparked considerable attention. His departure, effective at the end of April, follows a series of controversial actions during his tenure. A spokesman for the Department of Health and Human Services confirmed the news.
Controversial Tenure at the FDA
As the chief science and medical officer, Dr. Prasad held substantial authority over vaccine policies. His decisions often stirred debate.
- He frequently overruled career scientists on vaccine approvals.
- He took action against a biotech company associated with patient harm.
- He faced public backlash led by right-wing influencer Laura Loomer last summer, resulting in a brief dismissal.
Despite the controversy, Dr. Prasad was reinstated following appeals from Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary. His return, however, did not quell criticism.
Recent Criticisms
In the weeks leading up to his resignation, Dr. Prasad was criticized for the following:
- Rejecting treatments for rare diseases.
- Declining Moderna’s application for a new mRNA flu vaccine, a decision subsequently overturned by Dr. Makary.
Background and Previous Work
Before joining the FDA, Dr. Prasad was a faculty member at the University of California, San Francisco. Known for his contrarian views regarding COVID-19, he often criticized public health measures on social media and in podcasts.
He has been outspoken about the FDA’s approval standards, asserting they are too lenient. A senior administration official revealed that Dr. Prasad had taken a year-long leave from his academic position with plans to return.
Dr. Prasad’s exit from the FDA marks a notable shift in the agency’s approach to vaccine oversight amid ongoing debates over public health policies.
